Cargando…

New aspects of endocrine control of atrial fibrillation and possibilities for clinical translation

Hormones are potent endo-, para-, and autocrine endogenous regulators of the function of multiple organs, including the heart. Endocrine dysfunction promotes a number of cardiovascular diseases, including atrial fibrillation (AF). While the heart is a target for endocrine regulation, it is also an a...

Descripción completa

Detalles Bibliográficos
Autores principales: Aguilar, Martin, Rose, Robert A, Takawale, Abhijit, Nattel, Stanley, Reilly, Svetlana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8208746/
https://www.ncbi.nlm.nih.gov/pubmed/33723575
http://dx.doi.org/10.1093/cvr/cvab080
_version_ 1783708983156015104
author Aguilar, Martin
Rose, Robert A
Takawale, Abhijit
Nattel, Stanley
Reilly, Svetlana
author_facet Aguilar, Martin
Rose, Robert A
Takawale, Abhijit
Nattel, Stanley
Reilly, Svetlana
author_sort Aguilar, Martin
collection PubMed
description Hormones are potent endo-, para-, and autocrine endogenous regulators of the function of multiple organs, including the heart. Endocrine dysfunction promotes a number of cardiovascular diseases, including atrial fibrillation (AF). While the heart is a target for endocrine regulation, it is also an active endocrine organ itself, secreting a number of important bioactive hormones that convey significant endocrine effects, but also through para-/autocrine actions, actively participate in cardiac self-regulation. The hormones regulating heart-function work in concert to support myocardial performance. AF is a serious clinical problem associated with increased morbidity and mortality, mainly due to stroke and heart failure. Current therapies for AF remain inadequate. AF is characterized by altered atrial function and structure, including electrical and profibrotic remodelling in the atria and ventricles, which facilitates AF progression and hampers its treatment. Although features of this remodelling are well-established and its mechanisms are partly understood, important pathways pertinent to AF arrhythmogenesis are still unidentified. The discovery of these missing pathways has the potential to lead to therapeutic breakthroughs. Endocrine dysfunction is well-recognized to lead to AF. In this review, we discuss endocrine and cardiocrine signalling systems that directly, or as a consequence of an underlying cardiac pathology, contribute to AF pathogenesis. More specifically, we consider the roles of products from the hypothalamic-pituitary axis, the adrenal glands, adipose tissue, the renin–angiotensin system, atrial cardiomyocytes, and the thyroid gland in controlling atrial electrical and structural properties. The influence of endocrine/paracrine dysfunction on AF risk and mechanisms is evaluated and discussed. We focus on the most recent findings and reflect on the potential of translating them into clinical application.
format Online
Article
Text
id pubmed-8208746
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-82087462021-07-25 New aspects of endocrine control of atrial fibrillation and possibilities for clinical translation Aguilar, Martin Rose, Robert A Takawale, Abhijit Nattel, Stanley Reilly, Svetlana Cardiovasc Res Spotlight Reviews Hormones are potent endo-, para-, and autocrine endogenous regulators of the function of multiple organs, including the heart. Endocrine dysfunction promotes a number of cardiovascular diseases, including atrial fibrillation (AF). While the heart is a target for endocrine regulation, it is also an active endocrine organ itself, secreting a number of important bioactive hormones that convey significant endocrine effects, but also through para-/autocrine actions, actively participate in cardiac self-regulation. The hormones regulating heart-function work in concert to support myocardial performance. AF is a serious clinical problem associated with increased morbidity and mortality, mainly due to stroke and heart failure. Current therapies for AF remain inadequate. AF is characterized by altered atrial function and structure, including electrical and profibrotic remodelling in the atria and ventricles, which facilitates AF progression and hampers its treatment. Although features of this remodelling are well-established and its mechanisms are partly understood, important pathways pertinent to AF arrhythmogenesis are still unidentified. The discovery of these missing pathways has the potential to lead to therapeutic breakthroughs. Endocrine dysfunction is well-recognized to lead to AF. In this review, we discuss endocrine and cardiocrine signalling systems that directly, or as a consequence of an underlying cardiac pathology, contribute to AF pathogenesis. More specifically, we consider the roles of products from the hypothalamic-pituitary axis, the adrenal glands, adipose tissue, the renin–angiotensin system, atrial cardiomyocytes, and the thyroid gland in controlling atrial electrical and structural properties. The influence of endocrine/paracrine dysfunction on AF risk and mechanisms is evaluated and discussed. We focus on the most recent findings and reflect on the potential of translating them into clinical application. Oxford University Press 2021-03-16 /pmc/articles/PMC8208746/ /pubmed/33723575 http://dx.doi.org/10.1093/cvr/cvab080 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Spotlight Reviews
Aguilar, Martin
Rose, Robert A
Takawale, Abhijit
Nattel, Stanley
Reilly, Svetlana
New aspects of endocrine control of atrial fibrillation and possibilities for clinical translation
title New aspects of endocrine control of atrial fibrillation and possibilities for clinical translation
title_full New aspects of endocrine control of atrial fibrillation and possibilities for clinical translation
title_fullStr New aspects of endocrine control of atrial fibrillation and possibilities for clinical translation
title_full_unstemmed New aspects of endocrine control of atrial fibrillation and possibilities for clinical translation
title_short New aspects of endocrine control of atrial fibrillation and possibilities for clinical translation
title_sort new aspects of endocrine control of atrial fibrillation and possibilities for clinical translation
topic Spotlight Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8208746/
https://www.ncbi.nlm.nih.gov/pubmed/33723575
http://dx.doi.org/10.1093/cvr/cvab080
work_keys_str_mv AT aguilarmartin newaspectsofendocrinecontrolofatrialfibrillationandpossibilitiesforclinicaltranslation
AT roseroberta newaspectsofendocrinecontrolofatrialfibrillationandpossibilitiesforclinicaltranslation
AT takawaleabhijit newaspectsofendocrinecontrolofatrialfibrillationandpossibilitiesforclinicaltranslation
AT nattelstanley newaspectsofendocrinecontrolofatrialfibrillationandpossibilitiesforclinicaltranslation
AT reillysvetlana newaspectsofendocrinecontrolofatrialfibrillationandpossibilitiesforclinicaltranslation